Artios

DNA Damage Response | DDR Company | Artios Pharma

Cambridge, United Kingdom · Founded 2016 · $301.2M raised

Headquarters
Cambridge
Employees
51–200
Founded
2016
Business Model
B2B
Website
artios.com
Total Funding
$301.2M
Last Round
$115.0M Series DNov 2025
Rounds
3

About

Artios is a clinical-stage biopharmaceutical company focused on developing cancer therapies that target the DNA Damage Response pathway. Based at the Babraham Campus in Cambridge, UK, it has built a pipeline of DDR inhibitors including alnodesertib (ATR inhibitor) and a Pol Theta inhibitor program. Co-founded in 2016 by pioneering DDR researchers, Artios raised $115M in a Series D in 2025.

Summary

Artios is a Biotech company based in Cambridge, United Kingdom, founded in 2016. It has raised $301.2M in total across 3 rounds, most recently a $115.0M Series D round in Nov 2025. Investors include Omega Funds, TCGX and SV Life Sciences.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series DSeries DNov 2025
$115.0M

Sign up to see all 3 rounds

Series A through Series D — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Artios on Indexed.vc
<a href="https://indexed.vc/companies/artios"><img src="https://indexed.vc/api/badge/company/artios" alt="Artios on Indexed.vc" width="260" height="76" /></a>